One year after its Phase III failure in non-alcoholic steatohepatitis (NASH) with elafibranor, Genfit SA outlined its new R&D focus for investors on 11 May, headlined by a strategy to test a now-generic anti-infective drug in acute on chronic liver failure (ACLF). The French firm’s focus also remains on a pivotal Phase III study of elafibranor in second-line primary biliary cholangitis (PBC), as well as plans to test the drug and a second internally discovered PPAR agonist in first-line PBC as well as primary sclerosing cholangitis (PSC).
Genfit’s Post-NASH Plans Center On ACLF, Cholestatic Liver Disease
After last year’s Phase III failure in NASH, Genfit sees big opportunity in acute on chronic liver failure (ACLF), potentially with antiviral NTX. Its ongoing Phase III program in PBC as also is a potential revenue-driver.
More from Strategy
The Swiss-headquartered, NASDAQ-listed group has posted a Phase II win for OCS-05 in acute optic neuritis, which opens up its potential in additional, and much larger, neuro-ophthalmic indications, CEO Riad Sherif tells Scrip.
Plus deals involving Pfizer/Atavistik, Immedica/Marinus, J&J/Kaken, Ikena/Inmagene, Corxel/Vincentage, Rapt/Jemincare, Sanofi/Corxel, Bristol Myers Squibb/BioArctic, NGM/kdT Ventures and more.
Following promising Phase II data presented at ASH on the company's allogenic leukemia-derived dendritic cell vaccine, Mendus has secured support from the FDA and the EMA for pivotal studies starting later this year.
Neumora, one of two firms testing kappa opioid receptor antagonism in depression, failed its first of three Phase III studies. The company’s share price crashed sharply.